Thymectacin
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2S)-methyl 2-((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 232925-18-7 |
| ATC code | ? |
| PubChem | CID 6440764 |
| Chemical data | |
| Formula | C21H25BrN3O9P |
| Mol. mass | 574.3185 g/mol |
 (what is this?) (verify) |
|
Thymectacin (NB-1011, NB-101, N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer prodrug of brivudine monophosphate. It developed by New Biotics and it has entered in phase I clinical trials for colon cancer.[1]
[edit] References
- ^ Wilson, RH (2006). "Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer". The Oncologist 11 (9): 1018–1024. doi:10.1634/theoncologist.11-9-1018. PMID 17030644. http://theoncologist.alphamedpress.org/cgi/content/full/11/9/1018.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
